Singapoo - Kiingereza - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate eqv amoxycillin - capsule - 500 mg - amoxycillin trihydrate eqv amoxycillin 577.37 mg/capsule eqv 500mg amoxicillin

Singapoo - Kiingereza - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin sodium 1060.18 mg eqv. to amoxicillin free acid; potassium clavulanate 238.25 mg eqv. to clavulanic acid - injection, powder, for solution - 1 g/vial - amoxycillin sodium 1060.18 mg eqv. to amoxicillin free acid 1000 mg/vial; potassium clavulanate 238.25 mg eqv. to clavulanic acid 200 mg/vial

Singapoo - Kiingereza - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin sodium 530.09 mg eqv. to amoxicillin free acid; potassium clavulanate 119.13 mg eqv. to clavulanic acid - injection, powder, for solution - 500 mg/vial - amoxycillin sodium 530.09 mg eqv. to amoxicillin free acid 500 mg/vial; potassium clavulanate 119.13 mg eqv. to clavulanic acid 100 mg/vial

Singapoo - Kiingereza - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - mupirocin - ointment - 2% w/w - mupirocin 2% w/w

Singapoo - Kiingereza - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - salbutamol sulphate eqv salbutamol - injection - 5 mg/5 ml - salbutamol sulphate eqv salbutamol 5 mg/5 ml

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - 10 mcg/0.5ml - active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenoxyethanol sodium chloride thiomersal water for injection active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - engerix-b is indicated for active immunization against hepatitis b virus infection.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - 20 mcg/ml - active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenoxyethanol sodium chloride thiomersal water for injection active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - engerix-b is indicated for active immunization against hepatitis b virus infection.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - influenza virus a/california/7/2009 (h1n1) - like strain 30 µg/ml (a/christchurch/16/2010 (nib-74xp) (15 µg ha)); influenza virus a/hong kong/4801/2014 (h3n2) - like strain 30 µg/ml (a/hong kong/4801/2014, nymc x-263b (15 µg ha)); influenza virus b/brisbane/60/2008 - like strain 30 µg/ml (b/brisbane/60/2008 (15 µg ha)) - suspension for injection - active: influenza virus a/california/7/2009 (h1n1) - like strain 30 µg/ml (a/christchurch/16/2010 (nib-74xp) (15 µg ha)) influenza virus a/hong kong/4801/2014 (h3n2) - like strain 30 µg/ml (a/hong kong/4801/2014, nymc x-263b (15 µg ha)) influenza virus b/brisbane/60/2008 - like strain 30 µg/ml (b/brisbane/60/2008 (15 µg ha)) excipient: commercial light duty detergent d-alpha-tocopheryl acid succinate dibasic sodium phosphate dodecahydrate formaldehyde gentamicin sulfate magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium deoxycholate sucrose water for injection - fluarix is indicated for prophylaxis against influenza in adults and children older than six months of age.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml;  ; hepatitis a vaccine 1440 eu/ml - suspension for injection - 1440 eu/ml - active: hepatitis a vaccine 1440 eu/ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml;  ; hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml - suspension for injection - 720 elisa u/0.5ml - active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.